Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Conferences

10 March 2023

GenSight Biologics to Present at Upcoming Medical Conferences

29 September 2022

GenSight Biologics to Present at Upcoming 2022 Medical Conferences

20 September 2022

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

16 June 2022

GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022

28 Oct 2021 - 29 Oct 2021

Cell UK by Oxford’s Global, London (UK) & Virtual

25 Oct 2021 - 28 Oct 2021

BIO-Europe 2021, Virtual

15 Oct 2021 - 16 Oct 2021

Mitochondrial Diseases Conference 2021 by Mitocon, Virtual

19 Oct 2021 - 22 Oct 2021

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Virtual

12 Oct 2021 - 14 Oct 2021

2021 ARM Cell & Gene Meeting on the Mesa, Carlsbad, CA (USA) & Virtual

08 Oct 2021 - 12 Oct 2021

39th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), San Antonio, TX (USA)

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • View next 9 articles
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page